Investors
Oncopeptides strives to ensure that analysts, investors, shareholders and financial media are provided with correct information to enhance understanding of our operations.
Oncopeptides selected to present additional data from OCEAN study at the American Society of Hematology meeting
Oncopeptides announces that long-term outcomes from its Phase 3 OCEAN study has been accepted as a poster and will be presented at the 65th annual American Society of Hematology (ASH) Meeting and Exposition. The conference takes place in San Diego between December 9-12. The phase 3 OCEAN study is a global, randomized, head-to-head, open-label study, evaluating the efficacy and safety of melflufen and dexamethasone, versus pomalidomide and dexamethasone in patients with relapsed refractory multiple myeloma who have received 2-4 prior therapies.
Oncopeptides Chief Financial Officer Henrik Bergentoft takes office today
“I am happy to welcome Henrik who with his robust experience and personal qualities will constitute a major asset for Oncopeptides and its leadership,” says Sofia Heigis, CEO of Oncopeptides. “His more than 20 years of experience from leading finance roles at both medical and non-medical listed companies will be beneficial for us as we continue to build an organization designed for growth.”
Released November 8, 2023
Oncopeptides publishes Q3 report 2023
Download
“Providing clinical benefit to patients”
CEO Sofia Heigis
See the Webcast
For further information, please contact:
David Augustsson
Director Corporate Affairs
david.augustsson@oncopeptides.com
+46 762 29 38 68
Year-end report February 27, 2024
Press release - November 17, 2023
Article with exploratory alkylator-refractory subgroup analysis from Oncopeptides’ OCEAN study observing longer PFS and OS in melflufen vs. pomalidomide published in European Journal of Haematology
Read press releaseLatest press releases
German price of Pepaxti published
Oncopeptides recently successfully agreed on a reimbursed price for Pepaxti in Germany that in the company’s view reflects the innovation of the drug and is in line with the company’s financial projections. We can now present the updated list price for Pepaxti in Germany.
Oncopeptides publishes article in the Journal of Clinical Pharmacology
A new article on the Phamacokinetics and metabolism of melflufen, marketed in Europe as Pepaxti, in patients with Relapsed Refractory Multiple Myeloma was recently published in the Journal of Clinical Pharmacology, a journal designed to provide physicians, pharmacists, scientists and drug developers a forum to present research in all aspects of Clinical Pharmacology.
The third episode of Oncopeptalks – Industry Congresses
CEO Sofia Heigis and Director Corporate Affairs David Augustsson.
Upcoming events
New information regarding Oncopeptides’ appeal of U.S. withdrawal published
Additional information regarding the formal request from the U.S. Food and Drug Administration (FDA) to voluntarily withdraw Pepaxto´s approval in the U.S has been made available in the public docket.
Oncopeptides launches “Oncopeptalks” with a fireside chat featuring CEO Sofia Heigis
Join for the first edition of Oncopeptalks – a short company update aimed at investors where various members of the Oncopeptides team will be able to answer questions and address issues from the investor community.
CEO Sofia Heigis presented to Aktiespararna at Aktiedagen in Stockholm
On September 19, Sofia Heigis presented to Aktiespararna at Aktiedagen in Stockholm. During her presentation, followed by a question and answer session, Sofia reviewed some current events including the CHMP’s decision to recommend an approval for Pepaxti for earlier lines.
CHMP issues positive opinion on Type II variation to extend the therapeutic indication of Pepaxti based on OCEAN trial results
On September 14, Oncopeptides announced that the Committee for Medicinal Products for Human Use (CHMP), part of the European Medicines Agency (EMA), has, following their scientific assessment, adopted a positive opinion on Oncopeptides’ application for earlier lines of treatment for patients with relapsed, refractory multiple myeloma (RRMM). The opinion from the CHMP will now be sent to the European Commission for a final decision.
Oncopeptides publishes article on NK cell engagers in New Biotechnology
A new article, describing a set of affibody-based NK cell engagers using B cell maturation antigen (BCMA) as a model antigen for targeting of multiple myeloma, has been published online ahead of the November issue of New Biotechnology, the official journal of the European Federation of Biotechnology (EFB). Among the highlights of the article, dual engagers are found effective in activating resting NK cells and inducing a BCMA-dependent killing of MM cells.
Oncopeptides publishes two articles with results from ANCHOR and LIGHTHOUSE studies in Haematologica
Oncopeptides today, September 4, 2023, announces that two new articles with scientific data on melflufen, marketed in Europe as Pepaxti, has been published in Haematologica, a publication reporting on important findings in basic, clinical and translational research within hematology. The published data from two studies, ANCHOR and LIGHTHOUSE, provides additional scientific support for the clinical benefit of melflufen and dexamethasone in combination with daratumumab or bortezomib in relapsed refractory multiple myeloma (RRMM).
Sofia Heigis appointed CEO
On August 7, 2023, Oncopeptides announced that the Board of Directors has appointed Sofia Heigis as Chief Executive Officer, CEO, of Oncopeptides and replaces Monica Shaw. These changes are effective immediately.
Update following CHMP meeting
Following the June 19-22 CHMP meeting, Oncopeptides would like to clarify that the type II variation submission is running according to plan, and we are currently responding to the last couple of questions from the European Medicines Agency, EMA. We expect an opinion in Q3 2023.
Oncopeptides complete first sales of Pepaxti in Greece
Oncopeptides today announced its first named patient sales of its flagship drug Pepaxti in Greece. The sales were made possible through Oncopeptides’ partnership with Ariti S.A., a company specialized on medical and pharmaceutical supply in Greece.
Oncopeptides appoints David Augustsson as Director of Corporate Affairs
Oncopeptides AB today announced that David Augustsson has been appointed Director of Corporate Affairs. As part of the company leadership team, David will be responsible for corporate communications, including strengthening the relationship with its broad investor base, and also drive the effort to reshape the corporate strategy of the company and enable the execution of it.
Annual General Meeting on May 25
On Thursday, May 25, Oncopeptides hosted its 2023 Annual General Meeting. Be sure to watch the presentation held by Oncopeptides CEO Monica Shaw, or follow this link to find more information, including the bulletin from the meeting and the filmed Q&A session.
Investor Relations Contact
David Augustsson
Director of Corporate Affairs
Released April 25, 2023
Oncopeptides publishes the 2022 Annual Report
Download
Annual Report 2022
Letter from the CEO – Providing clinical benefit to patients
For further information, please contact:
David Augustsson
Director Corporate Affairs
david.augustsson@oncopeptides.com
+46 762 29 38 68
Presentations, webcasts and transcripts
See our latest Investor presentations, webcast, transcripts and interviews